Clinical utility of EBUS‐TBNA of hilar, interlobar, and lobar lymph nodes in patients with primary lung cancer. Issue 17 (20th July 2022)

• Record Type: Journal Article
• Authors: Wi, Seungbum; Kim, Bo‐Guen; Shin, Sun Hye; Jhun, Byung Woo; Yoo, Hongseok; Jeong, Byeong‐Ho; Lee, Kyungjong; Kim, Hojoong; Kwon, O Jung; Han, Joungho; Kim, Jhingook; Um, Sang‐Won
• Is Part Of: Thoracic cancer. Volume 13:Issue 17(2022)
• Page Start: 2507
• Page End: 2514
• Publication Date: 2022-07-20
• Subjects: endobronchial ultrasound‐guided transbronchial needle aspiration -- hilar lymph nodes -- lung cancer -- mediastinum -- staging; Chest -- Cancer -- Periodicals; Chest -- Cancer -- Treatment -- Periodicals; Chest -- Surgery -- Periodicals; 616.99494005
• DOI: 10.1111/1759-7714.14587
• Languages: English
• ISSNs: 1759-7706

Abstract

Abstract: Background: Endobronchial ultrasound‐guided transbronchial needle aspiration (EBUS‐TBNA) is used to evaluate hilar/interlobar/lobar lymph nodes. This study aimed to assess the clinical utility of EBUS‐TBNA for station 10/11/12 lymph nodes (LNs) in patients with primary lung cancer. Methods: This was a retrospective analysis of a prospectively collected database of patients with primary lung cancer who underwent EBUS‐TBNA for station 10/11/12 LNs from January 2015 to December 2019. Patients with benign results from EBUS‐TBNA who did not undergo surgical sampling/clinical follow‐up or who received radiotherapy/chemotherapy were excluded. Results: The analyses were conducted on 889 LNs from 797 patients. The overall diagnostic sensitivity, specificity, accuracy, negative predictive value (NPV), and positive predictive value of EBUS‐TBNA were 95.7, 100, 97.3, 93.2, and 100%, respectively. Diagnostic sensitivity was significantly lower for LNs <10 mm than ≥10 mm in size (90.1% vs. 97.8%; p < 0.001). There was no significant difference in diagnostic performance according to the nodal station (10 vs. 11/12) and left‐ versus right‐sided LNs. The diagnostic sensitivity (100 vs. 95.5%; p = 0.221) and specificity (100 vs. 100%) of N3 LNs was not significantly different from those of N1 LNs. In this study, eight (8/91, 8.8%) patients with cN1 NSCLC received neoadjuvant treatment based on the results of EBUS‐TBNA. Conclusion: EBUS‐TBNA accurately evaluates station 10/11/12 LNs of both N1 and N3 disease. The diagnostic performances of EBUS‐TBNA for station 10/11/12 LNs seem to be comparable to those of EBUS‐TBNA for mediastinal LNs. Abstract : Among 889 LNs from 797 patients, the overall diagnostic sensitivity, specificity, accuracy, negative predictive value, and positive predictive value of EBUS‐TBNA for station 10/11/12 LNs were 95.7, 100, 97.3, 93.2, and 100%, respectively. EBUS‐TBNA accurately evaluates station 10/11/12 LNs of both N1 and N3 disease. The diagnostic performances of EBUS‐TBNA for station 10/11/12 LNs seem to be comparable to those of EBUS‐TBNA for mediastinal LNs.